Page 630 - Read Online

Page 18 of 24 Peyvandi et al. J Cancer Metastasis Treat 2019;5:44 I http://dx.doi.org/10.20517/2394-4722.2019.16

40. Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013;13:727-38.
41. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012;21:283-96.
42. Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer 2018;18:669-80.
43. Monteiro J, Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer 2010;46:1198-203.
44. Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of
breast cancer metastasis. Breast Dis 2006;26:87-98.
45. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006;6:93-106.
46. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011;147:275-92.
47. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell 2017;168:670-91.
48. Badve S, Nakshatri H. Breast-cancer stem cells-beyond semantics. Lancet Oncol 2012;13:e43-8.
49. Antoniou A, Hebrant A, Dom G, Dumont JE, Maenhaut C. Cancer stem cells, a fuzzy evolving concept: a cell population or a cell
property? Cell Cycle 2013;12:3743-8.
50. Huang Z, Wu T, Liu AY, Ouyang G. Differentiation and transdifferentiation potentials of cancer stem cells. Oncotarget 2015;6:39550-63.
51. Bai X, Ni J, Beretov J, Graham P, Li Y. Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev 2018;69:152-63.
52. Smalley M, Piggott L, Clarkson R. Breast cancer stem cells: obstacles to therapy. Cancer Lett 2013;338:57-62.
53. Luo M, Brooks M, Wicha MS. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic
resistance. Curr Pharm Des 2015;21:1301-10.
54. Margaryan NV, Seftor EA, Seftor REB, Hendrix MJC. Targeting the stem cell properties of adult breast cancer cells: using combinatorial
strategies to overcome drug resistance. Curr Mol Biol Rep 2017;3:159-64.
55. Pinto CA, Widodo E, Waltham M, Thompson EW. Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for
chemoresistance. Cancer Lett 2013;341:56-62.
56. Hong D, Fritz AJ, Zaidi SK, van Wijnen AJ, Nickerson JA, et al. Epithelial-to-mesenchymal transition and cancer stem cells contribute to
breast cancer heterogeneity. J Cell Physiol 2018;233:9136-44.
57. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. Generation of breast cancer stem cells through epithelial-mesenchymal
transition. PLoS One 2008;3:e2888.
58. Vanharanta S, Massague J. Origins of metastatic traits. Cancer Cell 2013;24:410-21.
59. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306-13.
60. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-12.
61. Reeves MQ, Kandyba E, Harris S, Del Rosario R, Balmain A. Multicolour lineage tracing reveals clonal dynamics of squamous carcinoma
evolution from initiation to metastasis. Nat Cell Biol 2018;20:699-709.
62. Reiter JG, Makohon-Moore AP, Gerold JM, Heyde A, Attiyeh MA, et al. Minimal functional driver gene heterogeneity among untreated
metastases. Science 2018;361:1033-7.
63. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature
2010;467:1114-7.
64. Leung ML, Davis A, Gao R, Casasent A, Wang Y, et al. Single-cell DNA sequencing reveals a late-dissemination model in metastatic
colorectal cancer. Genome Res 2017;27:1287-99.
65. Desmedt C, Yates L, Kulka J. Catalog of genetic progression of human cancers: breast cancer. Cancer Metastasis Rev 2016;35:49-62.
66. Brown D, Smeets D, Szekely B, Larsimont D, Szasz AM, et al. Phylogenetic analysis of metastatic progression in breast cancer using
somatic mutations and copy number aberrations. Nat Commun 2017;8:14944.
67. Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer
Cell 2017;32:169-84.e7.
68. Kroigard AB, Larsen MJ, Laenkholm AV, Knoop AS, Jensen JD, et al. Clonal expansion and linear genome evolution through breast
cancer progression from pre-invasive stages to asynchronous metastasis. Oncotarget 2015;6:5634-49.
69. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, et al. Perioperative activation of disseminated tumor cells in bone marrow of
patients with prostate cancer. J Clin Oncol 2009;27:1549-56.
70. Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, et al. Direct genetic analysis of single disseminated cancer cells for
prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008;13:441-53.
71. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, et al. From latent disseminated cells to overt metastasis: genetic analysis of
systemic breast cancer progression. Proc Natl Acad Sci U S A 2003;100:7737-42.
72. Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, et al. Genomic analysis of single cytokeratin-positive cells from
bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005;8:227-39.
73. Biondini M, Duclos G, Meyer-Schaller N, Silberzan P, Camonis J, et al. RalB regulates contractility-driven cancer dissemination upon
TGFbeta stimulation via the RhoGEF GEF-H1. Sci Rep 2015;5:11759.
74. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002;4:487-94.
75. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting
inactivation of premature senescence. Cancer Cell 2008;14:79-89.
76. Naxerova K, Jain RK. Using tumour phylogenetics to identify the roots of metastasis in humans. Nat Rev Clin Oncol 2015;12:258-72.
77. Harper KL, Sosa MS, Entenberg D, Hosseini H, Cheung JF, et al. Mechanism of early dissemination and metastasis in Her2+ mammary
cancer. Nature 2016;540:588-92.
78. Marshall E. Cancer research and the $90 billion metaphor. Science 2011;331:1540-1.
79. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 2018;15:81-94.
80. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013;501:328-37.
81. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, et al. Non-cell-autonomous driving of tumour growth supports sub-clonal